Review
Medicine, General & Internal
Gerardo Rosati, Michele Montrone, Carmen Pacilio, Alfredo Colombo, Giuseppe Cicero, Fernando Paragliola, Angelo Vaia, Luigi Annunziata, Domenico Bilancia
Summary: Although colorectal cancer is increasingly diagnosed in older patients, their representation in clinical trials is insufficient, leading to unclear treatment guidelines. Targeted therapy for elderly patients with wild-type RAS and BRAF is challenging due to potential toxicity. Comprehensive geriatric assessment and recent studies provide important data for differentiating treatment outcomes based on functional status.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Luca Mastrantoni, Viria Beccia, Giulia Caira, Giovanni Trovato, Maria Alessandra Calegari, Michele Basso, Lisa Salvatore, Carmelo Pozzo, Giampaolo Tortora, Emilio Bria, Armando Orlandi
Summary: This study investigated maintenance therapy options for RAS wild type metastatic colorectal cancer. The results showed that FP + anti-EGFR treatment had the longest progression-free survival and was relatively safe. Anti-EGFR monotherapy may be considered for patients with left-sided tumors.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Giovanni Randon, Rona Yaeger, Jaclyn F. Hechtman, Paolo Manca, Giovanni Fuca, Henry Walch, Jeeyun Lee, Elena Elez, Jenny Seligmann, Benedetta Mussolin, Filippo Pagani, Marco Maria Germani, Margherita Ambrosini, Daniele Rossini, Margherita Ratti, Francesc Salva, Susan D. Richman, Henry Wood, Gouri Nanjangud, Annunziata Gloghini, Massimo Milione, Alberto Bardelli, Filippo de Braud, Federica Morano, Chiara Cremolini, Filippo Pietrantonio
Summary: EGFR amplification is significantly associated with left primary tumor sidedness and RAS/BRAF wild-type status. EGFR-amplified tumors are usually MSS and HER2 nonamplified, with a higher median fraction of genome altered. Patients with EGFR amplification tend to have longer overall survival and better outcomes when exposed to anti-EGFR-based therapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Oncology
Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang
Summary: Resistance to EGFR inhibitors in colorectal cancer is primarily due to the inability of the inhibitors to downregulate their target. The combination treatment with PEPDG278D overcomes this resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron J. Scott, Mohd Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P. Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P. Venook, W. Michael Korn, Heinz-Josef Lenz
Summary: Loss-of-function alterations in NF1 gene activate RAS, a driver of colorectal cancer. NF1-mutant tumors frequently also have mutations in PIK3CA and PTEN genes. Low NF1 expression may be associated with poor prognosis, while high expression may enhance the efficacy of cetuximab compared to bevacizumab. Further investigation in clinical settings is needed to explore the potential of NF1 alteration as a novel biomarker for targeted therapy.
Review
Oncology
Yong Li, Xian Chen, Wenzhu Li, Yongsong Ye, Xiaohua Du, Shaodan Sun, Lirong Liu, Haibo Zhang
Summary: This study reported a successful case of treating mCRC patient with cetuximab in combination with fruquintinib after resistance to chemotherapy, showing good response. The mechanisms of this combination therapy and other clinical research on combined treatments were discussed, highlighting the potential benefits of combining small-molecule anti-vascular drugs with anti-EGFR in CRC treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Jing Zhou, Qing Ji, Qi Li
Summary: The article discusses the resistance mechanisms to anti-EGFR monoclonal antibodies, as well as diverse approaches to reverse resistance to this therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang
Summary: The purpose of this study is to determine the impact of KRAS gene mutations on the efficacy of panitumumab monotherapy for metastatic colorectal cancer (mCRC). Through testing on 463 patients, it was found that 43% of patients had KRAS mutations. The results showed that panitumumab significantly improved overall survival and progression-free survival for patients with wild-type KRAS, while no significant efficacy was observed for patients with KRAS mutations. Therefore, KRAS status should be taken into account when selecting mCRC patients for panitumumab monotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Maochao Luo, Zhao Huang, Xingyue Yang, Yan Chen, Jingwen Jiang, Lu Zhang, Li Zhou, Siyuan Qin, Ping Jin, Shuyue Fu, Liyuan Peng, Bowen Li, Yongting Fang, Wenchen Pu, Yanqiu Gong, Yu Liu, Zhixiang Ren, Qiu-Luo Liu, Cun Wang, Fangqiong Xiao, Du He, Hongying Zhang, Changlong Li, Heng Xu, Lunzhi Dai, Yong Peng, Zong-Gung Zhou, Canhua Huang, Hai-Ning Chen
Summary: This study identifies PHLDB2 as a key player in latent liver metastasis of colorectal cancer (CRC). Chemotherapeutic-induced oxidative stress promotes N6-methyladenosine modification of PHLDB2 messenger RNA, leading to increased protein expression of PHLDB2. Upregulated PHLDB2 stabilizes EGFR and promotes its nuclear translocation, resulting in activation of EGFR signaling and resistance to cetuximab. The study proposes PHLDB2 as a potential target for CRC treatment.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, Francesca Bergamo, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Francesca Daniel, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchio, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Summary: This study aimed to use blood-based testing of RAS/BRAF/EGFR mutation levels to guide anti-EGFR therapy in patients with colorectal cancer. The results showed that rechallenge therapy with panitumumab, guided by liquid biopsies, had favorable outcomes compared to standard treatments. This suggests that liquid biopsies can effectively and safely guide treatment decisions in patients with mCRC.
Article
Oncology
Sanne ten Hoorn, Dirkje W. Sommeijer, Faye Elliott, David Fisher, Tim R. de Back, Anne Trinh, Lianne Koens, Tim Maughan, Jenny Seligmann, Matthew T. Seymour, Phil Quirke, Richard Adams, Susan D. Richman, Cornelis J. A. Punt, Louis Vermeulen
Summary: The study found that the efficacy of anti-EGFR therapy varies depending on different consensus molecular subtypes (CMSs) and primary tumor locations. The effectiveness of anti-EGFR therapy differs when using different chemotherapy backbones, showing favorable results in left-sided primary tumors with specific CMS subtypes. These findings suggest the potential for subtype-specific treatment strategies to optimize the use of anti-EGFR therapy.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, Chiara Carlotta Pircher, Paolo Manca, Francesca Bergamo, Mirella Giordano, Caterina Sposetti, Aldo Montagna, Guglielmo Vetere, Luca Zambelli, Cosimo Rasola, Alessandra Boccaccino, Filippo Pagani, Margherita Ambrosini, Marco Massafra, Gabriella Fontanini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
Summary: This study identified rare genomic alterations beyond RAS and BRAFV600E mutations that drive primary resistance to anti-EGFR therapy in metastatic colorectal cancer, highlighting the need for further investigation to maximize the benefit of EGFR blockade strategies.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Kaitao Yuan, Jinning Ye, Zhenguo Liu, Yufeng Ren, Weiling He, Jianbo Xu, Yulong He, Yujie Yuan
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Run Lin, Hui Zhang, Yujie Yuan, Qiong He, Jianwen Zhou, Shuhua Li, Yu Sun, Daniel Y. Li, Hai-Bo Qiu, Wei Wang, Zhehong Zhuang, Bin Chen, Yonghui Huang, Chuwei Liu, Yingzhao Wang, Shirong Cai, Zunfu Ke, Weiling He
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Jinning Ye, Liuhua Chen, Jidong Zuo, Jianjun Peng, Chuangqi Chen, Shirong Cai, Wu Song, Yulong He, Yujie Yuan
CANCER BIOLOGY & THERAPY
(2020)
Article
Oncology
Yuhui Zhang, Weibin Huang, Yujie Yuan, Jin Li, Jing Wu, Jie Yu, Yulong He, Zhewei Wei, Changhua Zhang
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2020)
Article
Medicine, General & Internal
Zhe-Wei Wei, Jing Wu, Wei-Bin Huang, Jin Li, Xiao-Fang Lu, Yu-Jie Yuan, Wen-Jun Xiong, Xin-Hua Zhang, Wei Wang, Yu-Long He, Chang-Hua Zhang
Article
Oncology
Zhe-Wei Wei, Wei-Bin Huang, Dong-Jie Yang, Yu-Jie Yuan, Yu-Long He, Chang-Hua Zhang
TRANSLATIONAL CANCER RESEARCH
(2020)
Review
Surgery
Yujie Yuan, Li Ding, Min Tan, An-jia Han, Xinhua Zhang
Summary: Inguinal hernia as a rare presentation of GIST is limitedly reported in the literature. Radical tumor resection plus hernia repair is the optimal surgical approach for such uncommon condition, with long-term results indicating an overall survival rate of approximately 64.3%.
Correction
Oncology
Yuhui Zhang, Weibin Huang, Yujie Yuan, Jin Li, Jing Wu, Jie Yu, Yulong He, Zhewei Wei, Changhua Zhang
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Zhenguo Liu, Ying Zhu, Yujie Yuan, Lei Yang, Kefeng Wang, Minghui Wang, Xiaoyu Yang, Xi Wu, Xi Tian, Rongguo Zhang, Bingqi Shen, Honghe Luo, Huiyu Feng, Shiting Feng, Zunfu Ke
Summary: A 3D DenseNet deep learning model based on preoperative CT imaging was developed to effectively detect myasthenia gravis in patients with thymoma. The model may serve as a supplement to conventional diagnostic criteria for identifying thymoma-associated myasthenia gravis.
FRONTIERS IN ONCOLOGY
(2021)
Review
Surgery
Kaitao Yuan, Man Shu, Yan Ma, Weidong Feng, Jinning Ye, Yujie Yuan
Summary: Bronchogenic cyst is a rare congenital anomaly that can present in the retroperitoneum. Surgical excision is the main treatment modality, with low risk of recurrence postoperatively.
Article
Oncology
Weigang Dai, Er-Tao Zhai, Jianhui Chen, Zhihui Chen, Risheng Zhao, Chuangqi Chen, Yujie Yuan, Hui Wu, Shirong Cai, Yulong He
Summary: The addition of No.12b and 12p lymph nodes to D2 lymphadenectomy in surgical treatment of advanced lower-third gastric cancer may be effective and improve oncological outcomes compared with No. 12a-based D2 lymphadenectomy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Wei Feng, Yongxin Zhang, Wenwei Liu, Xiaofeng Wang, Tianxiang Lei, Yujie Yuan, Zehong Chen, Wu Song
Summary: By analyzing the gene data of colorectal cancer (CRC) patients, we constructed a prognosis model based on immune genes and studied the immune mechanisms and therapeutic sensitivity of CRC. This is of great significance for the diagnosis and treatment of CRC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Qinbo Cai, Peng Shi, Yujie Yuan, Jianjun Peng, Xinde Ou, Wen Zhou, Jin Li, Taiqiang Su, Liangliang Lin, Shirong Cai, Yulong He, Jianbo Xu
Summary: The study revealed a new mechanism of H pylori-induced atrophic gastritis through CXCR2-mediated cellular senescence. Inhibition of CXCR2 signaling is suggested as a potential preventive therapy for targeting H pylori-induced atrophic gastritis.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, Research & Experimental
Jidong Zuo, Weixin Xiong, Jingfang Qiao, Ling Cheng, Qian Huang, Aili Li, Jia Cang, Shuwen Wu, Yujie Yuan, Min Tan
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
(2019)